炮制后含皂苷类中药对治疗心血管疾病疗效的影响及安全性研究  

Effect and safety analysis of traditional Chinese medicine processing on saponins in the treatment of cardiovascular diseases

作　　者：崔宁 贺玉莲 Cui Ning;He Yulian(Jinan Integrated Traditional Chinese and Western Medicine Hospital Pharmacy Department,Jinan,Shandong 271100,China)

机构地区：[1]济南市中西医结合医院,山东济南271100

出　　处：《首都食品与医药》2023年第9期157-160,共4页Capital Food Medicine

摘　　要：目的探究与分析炮制后含皂苷类中药对治疗心血管疾病疗效的影响及安全性。方法选取济南市中西医结合医院收治的心血管疾病患者120例,均为ST段抬高型心肌梗死患者,采用随机数字表法将其分为对照组与观察组,每组各60例,除去因中途出院、死亡以及各种原因导致的临床资料缺失者,共112例进入到了最终研究,对照组58例及观察组54例,对照组给予常规西医治疗,观察组在其基础上增加炮制后含皂苷类中药治疗,对比两组血管再通率、血管不良事件发生率;对比两组治疗前后左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、Morisky评分、冠心病自我管理量表(CSMS)评分;对比两组治疗前后心肌酶谱指标以及心脑血管损伤标志物指标水平;同时观察治疗期间不良反应。结果观察组与对照组相比血管再通率较高,血管不良事件发生率较低,差异有统计学意义(P<0.05)。观察组治疗后与对照组治疗后相比LVEF较高、LVEDD较低,Morisky评分较低,差异有统计学意义(P<0.05)。观察组治疗后与对照组治疗后相比CK值、GOT值、CK-MB值、BNP值、Hcy值及cTnT值均较低,差异有统计学意义(P<0.05)。两组治疗期间不良反应发生率相比,差异无统计学意义(P>0.05)。结论在常规西医治疗基础上增加中药炮制后含皂苷类中药对治疗ST段抬高型心肌梗死患者,可获得更高的血管再通率,降低血管不良事件发生风险,同时改善了心功能、心肌酶谱指标以及心脑血管损伤标志物指标,且治疗安全性有保障。Objective To explore and analyze the effect and safety of traditional Chniese medicine processing on saponins in the treatmen t of cardiovascular diseases.Methods A total of 120 cases of cardiovascular disease patients admitted to our hospital,all of whom were STsegment elevation myocardial infarction patients,were dividedin to control group and observation group by random number tabl emethod,with 60 cases in each group.Excluding those who were dischargde midway,died or had clinical data missing due to various reaosns,a total of 112 cases were included in the final study.There were 58 csaes in the control group and 54 cases in the observation group .The control group was treated with conventional western medicine,and the observation group was treated with traditional Chinese medicine processing p-saponins.The vascular revascularization rate and the incidence of vascular adverse events were compared between the two groups.Left ventricular ejection fraction(LVEF),left ventricular end-diastolic inner diameter(LVEDD),Morisky score and Coronary Heart Disease Self-Management Scale(CSMS)score before and after treatment were compared between the two groups.Myocardial enzyme profilea nd markers of cardiovascular and cerebrovascular injury were compared between the two groups before and after treatment.The adverse reactions during treatment were also observed.R esults Compared with the control group,the vascular revascularization rate was higher and the incidence of vascular adverse events was lower in the observation group,the difference was statistically significant(P<0.05).Compared with the control group after treatment,the observation group had higher LVEF,lower LVEDD and lower Morisky score,and the difference was statistically significant (P<0.05).The values of CK,GOT,CK-MB,BNP,Hcy and cTnT in theo bservation group after treatment were lower than those in the control group,and the difference was statistically significant (P<0.05).There was no significant difference in the incidence of vascular adverse events betweent

关 键 词：中药炮制 含皂苷类中药 心血管疾病 ST段抬高型心肌梗死 疗效 安全性 

分 类 号：R541[医药卫生—心血管疾病]